- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04348565
Diabetes Care Programme for Type 2 Diabetes Mellitus in Primary Care Setting
An Evaluation of the Effect of a Diabetes Care Programme for People With Type 2 Diabetes Mellitus in Primary Care Setting: A Randomized Controlled Trial
Uncontrolled metabolic parameters and co-morbidity risk factors cause Diabetes Mellitus as the leading cause of a multitude of micro-/macro-vascular complications. According to the International Guidelines and Recommendations, people with Type 2 Diabetes Mellitus (T2DM) should attend diabetes educational programmes periodically and optimize the metabolic index of control. In Hong Kong, General Practitioners with solo-practice (GP-SP) have the least availability of resources and support in DM management. A discrepancy of diabetes care between public and private settings and a gap of clinical practice between public-private healthcare settings is identified. In relation to the big population of T2DM is caring by GP-SP but no structured Diabetes Care Programme (DCP) is in place. A structured DCP for T2DM is in need to fill up the clinical gap and make beneficial to the target subjects.
The aim of this study is to evaluate the effectiveness of a DCP for people with T2DM in primary care settings. It is a multi-center, single-blind randomized controlled trial with parallel groups pre-test and post-test design. The evidence-based intervention (DCP) will be carried out in a private primary care setting. People with T2DM attending the GP-SP who meet the study criteria will be randomly assigned into one of the two study groups, either "DCP in addition to usual medical care" or "Usual medical care only" as a control group. The intervention group can beneficial in clinical and psychosocial outcomes after the completion of the 20-week structured DCP with a greater improvement of HbA1c level, Self-Efficacy in diabetes management, Diabetes Empowerment level, Diabetes Knowledge, and Quality of Life than those who only received usual medical care at the GP-SP.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
This study is to implement an evidence-based develop Diabetes Care Programme (DCP) for 152 adults with Type 2 Diabetes Mellitus (T2DM) in a few clinics of a general practitioner with solo-practice (GP-SP) in community, and evaluate its effectiveness by comparing the outcomes between study group (DCP with the usual medical care) and control group (Usual medical care only). It is believed that a structured DCP can promote greater clinical outcomes improvement and behavioral changes in the study group as evidence showed in literature. The primary outcomes are glycemic control (HbA1c level) and Self-Efficacy in diabetes management; whereas Diabetes Empowerment level, Diabetes Knowledge and Quality of Life are the secondary outcomes.
The DCP consists of two parts, conduct 3 interactive group education with an innovative educational tool "Diabetes Conversation Map™" sessions by dietitian and diabetes educator/nurse. Then it followed by another 8 weeks for delivering two 15-30 minutes teleconsultations for patient empowerment and follow-up of "Action Plan" by a diabetes educator/nurse. Evaluation of outcomes will be done before the DCP (baseline), at week-8 (right after the group sessions), and at week-20 (4 weeks after the last teleconsultation).
In addition, a focus group interview will be carried out after the completion of the whole intervention. It purposes to explore and get valuable descriptive information and feelings from participants about the intervention and diabetes self-management.
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Hau Yee H CHUNG
- Telefonní číslo: +852-9651-5919
- E-mail: harrietchung@link.cuhk.edu.hk
Studijní záloha kontaktů
- Jméno: Wai Tong CHIEN, Professor
- Telefonní číslo: +852-3943-8172
- E-mail: wtchien@cuhk.edu.hk
Studijní místa
-
-
Hong Kong SAR
-
Hong Kong, Hong Kong SAR, Hongkong, Hong Kong
- Nábor
- Clinics of private general practitioners
-
Kontakt:
- Kwok Wai A CHEUNG, Dr.
- Telefonní číslo: +852-9844-4955
- E-mail: alvinckw2000@yahoo.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- People with T2DM and follow up at private general practitioner
- Age 18-75
- Haemoglobin A1c (HbA1c) >7.0%
- Can communicate in Cantonese
Exclusion Criteria:
- Insulin users
- Unstable emotional and/or mental status
- Cognitive impairment and/or learning disabilities
- Recruited in other research and/or diabetes educational programme during the study period
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Podpůrná péče
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Diabetes Care Programme
People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who receive the intervention (Diabetes Care Programme) in addition to usual medical care at the GP
|
20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
|
Žádný zásah: Standard Usual Care
People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who only receive the usual medical care at the GP
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Glycated haemoglobin (HbA1c)
Časové okno: Change from Baseline HbA1c at week 20
|
Glycemic control
|
Change from Baseline HbA1c at week 20
|
Self-efficacy level in diabetes management
Časové okno: Change from Baseline Self-efficacy level at week 8
|
To assess the Self-efficacy level in diabetes management of Chinese people with diabetes.
Includes 20 items of self-care in six domains with 1-10 rating scale.
Higher score means better self-care.
|
Change from Baseline Self-efficacy level at week 8
|
Self-efficacy level in diabetes management
Časové okno: Change from Baseline Self-efficacy level at week 20
|
To assess the Self-efficacy level in diabetes management of Chinese people with diabetes.
Includes 20 items of self-care in six domains with 1-10 rating scale.
Higher score means better self-care.
|
Change from Baseline Self-efficacy level at week 20
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Diabetes Empowerment Scale
Časové okno: Change from Baseline Psycho-social Self-efficacy level at week 8
|
To assess the overall psycho-social self-efficacy level of Chinese people with diabetes.
It includes 10 items with a 1-5 rating scale.
A higher score means a higher level of self-efficacy.
|
Change from Baseline Psycho-social Self-efficacy level at week 8
|
Diabetes Empowerment Scale
Časové okno: Change from Baseline Psycho-social Self-efficacy level at week 20
|
To assess the overall psycho-social self-efficacy level of Chinese people with diabetes.
It includes 10 items with a 1-5 rating scale.
A higher score means a higher level of self-efficacy.
|
Change from Baseline Psycho-social Self-efficacy level at week 20
|
Diabetes Knowledge Questionnaire
Časové okno: Change from Baseline Diabetes self-care knowledge at week 8
|
To assess the Diabetes self-care knowledge of Chinese people with diabetes.
It includes 24 items of diabetes self-care knowledge with the total score range from 0-24.
Valid responses with "yes", "no" or "I don't know"; only scored on correct answers.
A higher score means a higher level of diabetes knowledge.
|
Change from Baseline Diabetes self-care knowledge at week 8
|
Diabetes Knowledge Questionnaire
Časové okno: Change from Baseline Diabetes self-care knowledge at week 20
|
To assess the Diabetes self-care knowledge of Chinese people with diabetes.
It includes 24 items of diabetes self-care knowledge with the total score range from 0-24.
Valid responses with "yes", "no" or "I don't know"; only scored on correct answers.
A higher score means a higher level of diabetes knowledge.
|
Change from Baseline Diabetes self-care knowledge at week 20
|
Quality of life Measurement
Časové okno: Change from Baseline Quality of Life status at week 8
|
The valuation of health status (quality of life) of Chinese people.
It includes 5 health dimensions with a sum of negative validity & 1 visual analog scale to reflect the self-rated health score.
A higher score means a higher quality of life status.
|
Change from Baseline Quality of Life status at week 8
|
Quality of life Measurement
Časové okno: Change from Baseline Quality of Life status at week 20
|
The valuation of health status (quality of life) of Chinese people.
It includes 5 health dimensions with a sum of negative validity & 1 visual analog scale to reflect the self-rated health score.
A higher score means a higher quality of life status.
|
Change from Baseline Quality of Life status at week 20
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Hau Yee H CHUNG, Chinese University of Hong Kong
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CREC2019.290
- Clinical Research Ethics (Jiný identifikátor: Joint CUHK-NTEC CREC)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Diabetes mellitus, typ 2
-
Hoffmann-La RocheDokončenoDiabetes 2. typu, Diabetes 1. typuRakousko, Spojené království
-
Services Hospital, LahoreDokončeno
-
Griffin HospitalCalifornia Walnut CommissionDokončenoDIABETES MELLITUS TYP 2Spojené státy
-
West China HospitalDokončeno
-
University of Roma La SapienzaNeznámýDiabetes Mellitus Typ 2 Reaktivita krevních destiček StatinItálie
-
Bristol-Myers SquibbDokončenoDiabetes, typ 2Spojené státy, Kanada, Mexiko, Portoriko, Austrálie, Polsko, Tchaj-wan
-
Universidade Federal de Ouro PretoDokončeno
-
Novo Nordisk A/SNáborDiabetes, typ 2Spojené státy, Indie, Španělsko, Polsko, Jižní Afrika, Bulharsko, Německo, Japonsko, Portoriko
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Churchill HospitalDokončenoDiabetes, typ 2Spojené království
-
Kyowa Kirin Co., Ltd.Dokončeno
Klinické studie na Diabetes Care Programme
-
University of BremenGerman Federal Ministry of Education and Research; Institute of Public Health... a další spolupracovníciNeznámýÚnava související s rakovinou
-
Chunrui LiNanjing IASO Biotechnology Co., LtdNáborStudie CAR-GPRC5D u pacientů s relapsem/refrakterním mnohočetným myelomem nebo plazmatickou leukémiíPlazmabuněčná leukémie | Recidivující/refrakterní mnohočetný myelomČína
-
Cellular Biomedicine Group Ltd.The First Affiliated Hospital with Nanjing Medical UniversityDokončenoRefrakterní difúzní velký B-buněčný lymfomČína
-
Nexcella Inc.Zatím nenabírámeAmyloidóza lehkého řetězce (AL).Spojené státy
-
Second Affiliated Hospital, School of Medicine,...NáborRecidivující a refrakterní B-buněčný lymfomČína
-
Second Affiliated Hospital, School of Medicine,...NáborB-buněčný non Hodgkinův lymfomČína
-
Daniel LandiUkončenoGlioblastom | GliosarkomSpojené státy
-
Hebei Senlang Biotechnology Inc., Ltd.NáborLymfom | Mnohočetný myelom | Akutní lymfoblastická leukémieČína
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...StaženoAkutní lymfoblastická leukémie | Non-hodgkinský lymfomSpojené státy
-
Nanjing IASO Biotechnology Co., Ltd.Ruijin HospitalNáborStudie CAR-GPRC5D u pacientů s relapsem/refrakterním mnohočetným myelomem nebo plazmatickou leukémiíPlazmabuněčná leukémie | Recidivující/refrakterní mnohočetný myelomČína